SCHEMBL3749166

SCHEMBL3749166

COc1c(C)c(/C=C/C(=O)O)c(OC)c(OC)c1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
KDM4E B2RXH2 7/20 0.47
HPGD P15428 3/20 0.47
HSD17B10 Q99714 2/20 0.47
HTR1A P08908 1/20 0.47
HTR2C P28335 1/20 0.47
APEX1 P27695 1/20 0.42
THRB P10828 1/20 0.42
ATM Q13315 1/20 0.42
PKM P14618 2/20 0.40
PTGS2 P35354 2/20 0.40
GAA P10253 2/20 0.40
PTGS1 P23219 1/20 0.40
NPC1 O15118 1/20 0.40
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
CNKSR1 Q969H4 1/20 0.37
ABCC4 O15439 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3749174 1.00 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL10474937 0.85 GAA (0.47) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL10474939 0.85 GAA (0.47) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL28793561 0.77 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL9510807 0.76 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL9510800 0.76 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL23706403 0.75 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL23706404 0.75 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL10406293 0.74 ALDH1A1 (0.38) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL18662483 0.74 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2203161-B1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF UNIV INDIANA RES & TECH CORP (US) 2018-05-09 EP disclosed
US-9089605-B2 Quinone derivatives, pharmaceutical compositions, and uses thereof INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2015-07-28 US disclosed
US-20100297113-A1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF PURDUE RESEARCH FOUNDATION 2010-11-25 US disclosed
US-20100297113-A1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF PURDUE RESEARCH FOUNDATION 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297113-A1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF APEX1, NQO1, REV1 ALDH1A1 210/4885SMN1; SMN2 4316/4885KDM4E 2642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.